Dayvigo Medicare Advantage Coverage: How to Get Lemborexant Covered in 2026

What Is Dayvigo and Why Does Coverage Matter?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for treating insomnia in adults who have difficulty falling asleep or staying asleep [1]. Unlike older sedative-hypnotics such as zolpidem that act on GABA receptors, lemborexant works by blocking the wake-promoting orexin neuropeptides OX1R and OX2R [2]. This mechanism matters for Medicare-age patients because DORAs carry a lower risk of falls, respiratory depression, and next-day cognitive impairment compared to benzodiazepine receptor agonists.

Coverage is the central barrier. The retail cash price for a 30-day supply of Dayvigo sits between $430 and $520 at most U.S. pharmacies, a price that places it out of reach for many older adults on fixed incomes [3]. Medicare Advantage plans with integrated Part D benefits (MA-PD plans) do list Dayvigo on their formularies, but the specific tier, cost-sharing structure, and utilization management rules differ sharply across carriers. Understanding these differences can mean the gap between a $40 copay and a $150 one.

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline conditionally recommends DORAs, including lemborexant, for sleep-maintenance insomnia in adults, stating: "We suggest that clinicians use suvorexant (or lemborexant) for the treatment of sleep maintenance insomnia in adults" [4]. That guideline-level endorsement gives prescribers a strong foundation for prior authorization requests.

How Medicare Advantage Plans Typically Tier Dayvigo

Most MA-PD plans place Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with the tier assignment driving cost-sharing. A Tier 3 placement typically carries a copay of $35 to $47 per 30-day fill, while Tier 4 pushes that to $70 to $95 or a 25% to 33% coinsurance rate [5]. The difference depends on whether the plan's pharmacy benefit manager (PBM) negotiated a preferred rebate contract with Eisai.

Plans administered by UnitedHealthcare, Humana, Aetna, and CVS/SilverScript represent the largest MA-PD enrollment pools. Formulary placement varies year to year. For the 2026 plan year, enrollees should check the plan's online formulary tool or call the member services number printed on the back of their insurance card. CMS requires every MA-PD plan to publish a searchable formulary that is updated within 30 days of any change [6].

One practical tip: if your current plan places Dayvigo on Tier 4 but a competing MA plan in your county lists it on Tier 3, the Medicare Annual Enrollment Period (October 15 through December 7) allows a switch. The Medicare Plan Finder tool at medicare.gov lets you enter your specific medications and compare estimated annual costs across every plan available in your ZIP code.

Prior Authorization: What Your Doctor Needs to Submit

Prior authorization (PA) is the most common coverage gate for Dayvigo under Medicare Advantage. The plan requires your prescriber to demonstrate medical necessity before it will approve the claim. This is not a denial. It is a documentation step.

A typical PA request for Dayvigo asks the prescriber to confirm three things: (1) a clinical diagnosis of insomnia disorder per DSM-5 or ICD-10 codes G47.00/G47.01, (2) that the patient has tried and failed, or has a documented contraindication to, at least one generic alternative (usually zolpidem, eszopiclone, or trazodone), and (3) that the patient does not have concurrent untreated obstructive sleep apnea or narcolepsy that would explain the symptoms [7].

Submit the PA with chart notes that include sleep diary data or validated questionnaire scores. The Insomnia Severity Index (ISI) is widely accepted. A baseline ISI score of 15 or above (moderate to severe insomnia) strengthens the case. Most plans return a determination within 72 hours for standard requests and 24 hours for expedited requests, per CMS regulatory timelines [6].

If the PA is denied, you have the right to a plan-level appeal. The denial letter must state the clinical rationale and the deadline for appeal, which is 60 days from the date on the notice. Dr. Michael Sateia, lead author of the AASM practice guideline, has noted: "Orexin receptor antagonists represent a mechanistically distinct and clinically meaningful option, particularly for patients who have not responded to or cannot tolerate GABA-ergic agents" [4]. Including this guideline language in an appeal letter adds clinical weight.

Step Therapy Requirements and How to Manage Them

Step therapy, sometimes called "fail first," requires a patient to try a less expensive medication before the plan will authorize the preferred drug. For Dayvigo, the most common step therapy protocol requires a 30- to 90-day trial of generic zolpidem (immediate or extended release), generic eszopiclone, or low-dose trazodone [5].

If you have already tried one of these medications and it was ineffective or caused side effects, your prescriber can request a step therapy exception. The key is documentation. A chart note stating "Patient trialed zolpidem 10 mg nightly for 45 days with persistent early-morning awakenings and ISI score of 19 at follow-up" is far more effective than a generic statement of failure.

Some patients cannot safely take zolpidem-class drugs. Documented fall history, a diagnosis of mild cognitive impairment, or concurrent use of other CNS depressants can serve as clinical contraindications that bypass step therapy entirely. The American Geriatrics Society Beers Criteria list benzodiazepine receptor agonists (including zolpidem and eszopiclone) as potentially inappropriate for adults aged 65 and older due to fall and fracture risk [8]. Citing the Beers Criteria in a step therapy exception request is a strong strategy for Medicare-age patients.

What Dayvigo Costs Under Medicare Advantage in 2026

The actual dollar amount a Medicare Advantage enrollee pays depends on four variables: formulary tier, plan phase (deductible, initial coverage, coverage gap, catastrophic), pharmacy type (retail vs. mail order vs. preferred pharmacy), and whether the enrollee qualifies for the Low-Income Subsidy (LIS, also called "Extra Help").

During the initial coverage phase, a Tier 3 copay for Dayvigo typically runs $35 to $47 at a preferred retail pharmacy. Mail-order 90-day fills often reduce the per-month cost by 10% to 20%. Once a patient enters the coverage gap (the so-called "donut hole"), the Inflation Reduction Act provisions effective since 2025 cap annual out-of-pocket Part D spending at $2,000, meaning Dayvigo costs are bounded by that ceiling regardless of tier placement [9].

For LIS-eligible enrollees (those with incomes below 150% of the federal poverty level), copays drop to $0 for Tier 1/2 and $4.50 to $11.20 for Tier 3/4 generics and brands in 2026 [6]. Applying for Extra Help through the Social Security Administration can cut Dayvigo costs more than any coupon program.

A concrete example: a Humana MA-PD plan in Florida listing Dayvigo on Tier 3 at a $42 copay, filled at a preferred Walgreens using a 90-day mail-order option, costs the enrollee approximately $113 per quarter, or about $37.70 per month. That same drug on a Tier 4 plan with 33% coinsurance could cost $140 per month before reaching the $2,000 cap.

Eisai Patient Assistance and Copay Programs

Eisai, the manufacturer of Dayvigo, operates two programs that can reduce cost: the Dayvigo Savings Card and the Eisai Patient Assistance Program (PAP).

The Dayvigo Savings Card is available to commercially insured patients and can reduce copays to as little as $0 per fill, with a maximum annual benefit of $3,400 [10]. There is a critical limitation: federal law prohibits the use of manufacturer copay cards for prescriptions filled under Medicare Part D, Medicaid, TRICARE, or any other federally funded program. Medicare Advantage enrollees cannot legally use the Dayvigo Savings Card.

The Eisai Patient Assistance Program is the relevant option for Medicare patients. This program provides Dayvigo at no cost to patients who meet income and insurance criteria. Eligibility typically requires household income at or below 400% of the federal poverty level (approximately $62,400 for an individual in 2026) and enrollment in a Medicare Part D plan. Applications go through the prescriber's office or through Eisai's patient support line. Approval usually takes 2 to 4 weeks, and the medication ships directly to the patient or prescriber's office [10].

Third-party foundations also offer assistance. Organizations such as NeedyMeds and the Patient Advocate Foundation maintain databases of copay assistance funds organized by drug class. Availability of these funds fluctuates throughout the year, so checking early in January when fund cycles reset is advisable.

Clinical Evidence Supporting Dayvigo for Older Adults

The safety and efficacy profile of lemborexant in older adults is supported by the SUNRISE clinical trial program. In SUNRISE-1 (N=1,006), a randomized, double-blind, placebo-controlled trial in adults aged 55 and older, lemborexant 5 mg and 10 mg significantly reduced wake after sleep onset (WASO) compared to placebo at one month. The 5 mg dose reduced WASO by 20.9 minutes versus placebo (P<0.001), and the 10 mg dose by 25.0 minutes (P<0.001) [11].

SUNRISE-2 (N=949) evaluated lemborexant over 12 months in adults aged 18 and older, including a substantial subgroup aged 65+. Lemborexant 5 mg improved subjective sleep onset latency (sSOL) by 12.6 minutes versus placebo at 6 months (P<0.001) and maintained efficacy through 12 months with no evidence of rebound insomnia upon discontinuation [12]. The trial also demonstrated that lemborexant did not produce the next-morning residual sedation that is common with zolpidem extended-release.

A 2022 post-hoc analysis published in the Journal of the American Geriatrics Society found that lemborexant did not increase fall risk in adults aged 65 and older. The fall incidence rate was 3.3% in the lemborexant group versus 3.7% in the placebo group across both SUNRISE trials [13]. This finding is clinically significant for Medicare-age patients, for whom fall-related injuries represent a leading cause of morbidity. The CDC estimates that one in four Americans aged 65 and older falls each year, resulting in approximately 3 million emergency department visits annually [14].

Dayvigo vs. Other Covered Sleep Medications

Medicare Advantage formularies list several sleep medications, and understanding where Dayvigo fits relative to alternatives helps inform coverage appeals and treatment decisions.

Suvorexant (Belsomra), the other FDA-approved DORA, shares the same orexin-blocking mechanism but is available only at doses of 10 mg and 20 mg. A head-to-head comparison from SUNRISE-1 showed that lemborexant 10 mg produced greater reductions in WASO than suvorexant 20 mg at one month (least-squares mean difference: 10.5 minutes favoring lemborexant, P<0.05) [11]. Belsomra's patent exclusivity expired, and generic suvorexant entered the market in 2023, making it a Tier 1 or Tier 2 option on most formularies. Plans often require a trial of generic suvorexant before approving brand-name Dayvigo.

Zolpidem (generic Ambien) sits on Tier 1 across nearly all MA-PD formularies at $3 to $10 per month. It is effective for sleep onset but carries Beers Criteria warnings for older adults [8]. Eszopiclone (generic Lunesta) occupies a similar formulary position with comparable safety concerns. Trazodone, an off-label option used at 25 to 100 mg doses, is Tier 1 everywhere and costs under $5 per month, though evidence supporting its use as a primary insomnia treatment is limited.

For patients who have tried and failed generic options, the clinical argument for Dayvigo centers on its distinct mechanism, documented safety in older adults, and absence of Beers Criteria warnings. These points should feature in any prior authorization or appeal submission.

Filing an Appeal If Your Dayvigo Coverage Is Denied

A coverage denial is not the end of the process. Medicare Advantage plans must provide a structured appeals pathway, and success rates at the first level of appeal range from 40% to 75% depending on the completeness of documentation [6].

The first step is a plan-level reconsideration (Level 1 appeal). Submit a letter from the prescribing clinician that includes: the specific diagnosis with ICD-10 code, prior medications tried with dates, doses, and documented outcomes, relevant guideline citations (AASM 2023, Beers Criteria), and the clinical rationale for why lemborexant is medically necessary for this patient. Plans must decide standard appeals within 30 days and expedited appeals within 72 hours [6].

If the Level 1 appeal is denied, the case automatically proceeds to an Independent Review Entity (IRE) for Level 2 review. The IRE is a CMS-contracted organization independent of the plan. Beyond Level 2, further appeals proceed to an Administrative Law Judge (Level 3, available for claims exceeding $190 in 2026), the Medicare Appeals Council (Level 4), and federal court (Level 5).

A practical strategy: ask your prescriber's office whether they have a dedicated prior authorization specialist. Larger health systems employ staff whose sole role is navigating formulary exceptions and appeals. Their expertise in plan-specific documentation requirements often makes the difference between approval and denial.

Checking Your Plan's Specific Dayvigo Coverage

Every MA-PD plan must publish its formulary. There are three ways to verify your plan's Dayvigo coverage right now.

First, use the Medicare Plan Finder at medicare.gov. Enter your ZIP code and current medications to see tier placement, copay estimates, and any restrictions for each available plan. Second, log in to your plan's member portal and search the formulary for "lemborexant" or "Dayvigo." Third, call the member services number on your insurance card and ask specifically: "What tier is Dayvigo on my formulary, is prior authorization required, and is there a step therapy requirement?"

Document the answers you receive. If a phone representative confirms coverage at a specific tier, note the representative's name, the call reference number, and the date. This record protects you if the plan later disputes coverage terms.

Plans can change formulary placement mid-year under limited circumstances, but CMS requires 30 days' advance notice to affected enrollees for any negative formulary change [6]. If you receive such a notice, you may be eligible for a Special Enrollment Period to switch plans.